Clinical trials: Histological Type of Neoplasm
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
To analyze the occurrence of transformation from myelodysplastic syndrome (MDS) to acute myeloid leukemia (hereinafter referred to as transformation from MDS to AML) in patients with myelodysplastic syndrome with a deletion 5q…
- Trial name
- NCT02921815
- Where
- Japan
- Volunteers
- 84 people
- Sponsor
- Celgene
Soft Tissue Sarcoma, High Risk of Recurrence
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma
- Conditions
- Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib, Radiotherapy
- Trial name
- NCT05602415
- Testing
- Anlotinib, Radiotherapy, Surgery
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Ruijin Hospital
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00096525
- Testing
- lenalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03873818
- Testing
- Ipilimumab, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is metastatic to the skin.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer
- Trial name
- NCT00023790
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Osteosarcoma
Monocyte Phenotypic and Functional Differences
The purpose of this study is to identify phenotypic (cell surface receptor expression) and functional differences in monocyte populations in humans with osteosarcoma as compared to published historical data on normal human…
- Trial name
- NCT02132182
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Lymphoma, Extranodal NK-T-Cell
MESA Treatment for NK/T Cell Lymphoma
Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma
- Trial name
- MTN (NCT01933282)
- Testing
- MESA chemotherapy, MESA
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Air Force Military Medical University, China
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
This is a CUP which is designed to provide treatment access of STS to pediatric patients for the protection from Cisplatin-Induced Hearing Loss in children who had standard-risk hepatoblastoma.
- Trial name
- NCT04132882
- Testing
- Sodium Thiosulfate (STS)
- Where
- Turkey (Türkiye)
- Sponsor
- TRPHARM
Lymphoma, Hodgkin
MELT - MRI Evaluation of Lymphoma Treatment
Patients who are newly diagnosed with Hodgkin's lymphoma will undergo disease staging at diagnosis and initial treatment response assessment.
- Trial name
- MELT (NCT01459224)
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- University College, London
Non-Hodgkin's Lymphoma
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments.
- Trial name
- NCT00323323
- Testing
- CHOP, Alemtuzumab, Plasma Samples
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Neck Mass, Thyroglossal Duct Cysts
Computer Aided Tool for Diagnosis of Neck Masses in Children
The aim of this study was to evaluate the diagnostic efficacy of computer aided diagnostic tool for neck masses using machine learning and deep learning techniques on clinical information and radiological images in children.
- Conditions
- Neck Mass, Thyroglossal Duct Cysts, Branchial Cleft Anomalies, Dermoid and Epidermoid Cysts
- Trial name
- NCT05187923
- Testing
- Artificial Intelligence Algorithm
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- West China Hospital
Mycosis Fungoides
BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma
Background - Advanced cutaneous T-cell lymphoma (mycosis fungoides, MF) is an incurable extranodal mature lymphoma with poor prognosis. Currently available therapies provide only short-term remissions.
- Trial name
- BIOSELECT (NCT05538988)
- Testing
- Cemiplimab
- Where
- Canada
- Sponsor
- AHS Cancer Control Alberta
Invasive Ductal Breast Cancer, Carcinoma Breast Stage I
Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)
The overall objective of this study is to determine the feasibility and tolerability of single dose Intraoperative Electron Radiation Treatment ("IOERT") as definitive therapy when administered at the time of breast conserving…
- Trial name
- NCT01960803
- Testing
- Intraoperative Electron Radiotherapy
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Hepatocellular Carcinoma
Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC
The incidence of Hepatocellular carcinoma (HCC) is increasing worldwide. However, most of HCC cases were at advanced stage when the diagnosis established.Early diagnosis improves the prognosis.The study is intended to evaluate…
- Trial name
- NCT03047603
- Testing
- PIVKA-II
- Where
- China
- Volunteers
- 4,005 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject.
- Trial name
- Hydeal Cyst (NCT06245603)
- Testing
- Hydeal Cyst®
- Where
- 9 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Carcinoma, Hepatocellular, Gastric Adenocarcinoma
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in…
- Conditions
- Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer
- Trial name
- VALUE-CHECK (NCT06422403)
- Testing
- Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C
- Where
- Singapore
- Volunteers
- 360 people
- Sponsor
- National University Hospital, Singapore
NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, Metabolic Syndrome
- Trial name
- PROMETEO (NCT04371042)
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Advanced Solid Malignancies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that…
- Trial name
- CERTIS1 (NCT05417594)
- Testing
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
AML, Multiple Myeloma
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
To assess safety and tolerability at increasing dose levels of 6MW5311 in successive cohorts of participants with MM, AML and CMML in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose…
- Conditions
- AML, Multiple Myeloma, CMML
- Trial name
- NCT07914556
- Testing
- 6MW5311
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.